help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Levine, A. C.
Right arrow Articles by Kirschenbaum, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Levine, A. C.
Right arrow Articles by Kirschenbaum, A.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Endocrinology Vol. 139, No. 11 4672-4678
Copyright © 1998 by The Endocrine Society

ARTICLES

Androgens Induce the Expression of Vascular Endothelial Growth Factor in Human Fetal Prostatic Fibroblasts1

Alice C. Levine, Xin-Hua Liu, Pietra D. Greenberg, Mark Eliashvili, Jonathan D. Schiff, Stuart A. Aaronson, James F. Holland and Alexander Kirschenbaum

Department of Medicine, Division of Endocrinology (A.C.L., P.D.G., M.E., J.D.S.), Division of Neoplastic Diseases (J.F.H.), Derald H. Ruttenberg Cancer Center (S.A.A.), and Department of Urology (X.-H.L., A.K.), Mount Sinai School of Medicine, New York, New York 10029

Address all correspondence and requests for reprints to: Dr. Alice C. Levine, Box 1055, Department of Medicine, Mount Sinai Medical Center, 1 Gustave L. Levy Place, New York, New York 10029.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Androgens are known to directly stimulate prostate cancer cell growth. We have previously reported that LNCaP prostate cancer cells were dependent upon stromal coinoculation for growth in nude mice and that the stromal cells secreted a potent angiogenic factor, vascular endothelial growth factor (VEGF), which stimulated tumor angiogenesis. Immunohistochemical staining localized VEGF expression primarily to the stromal cells of human fetal and adult hyperplastic prostates, with both stromal and epithelial cell VEGF expression in prostate cancer. In the present studies, we test the hypothesis that androgens, in addition to their direct effects on prostate epithelial cells, have indirect effects on these cells via up-regulation of stromal VEGF production and angiogenesis. Primary cultures of human prostate fetal fibroblasts were treated with dihydrotestosterone (DHT), and the effects on VEGF messenger RNA (mRNA) expression were determined by Northern blotting. DHT (10 nM) increased VEGF mRNA levels maximally after 2 h. Nuclear run-on transcription assays demonstrated a 2-fold increase in the VEGF transcription rate 2 h after the addition of DHT. VEGF mRNA stability was unaffected by DHT addition. VEGF protein levels were determined by enzyme-linked immunosorbent assay and were increased 2-fold 4 h after DHT addition. These data indicate that androgens increase VEGF transcription and secretion of biologically active VEGF from human prostatic stroma. Androgens, therefore, may indirectly enhance prostate growth via up-regulation of VEGF from the surrounding stroma.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
STROMAL-EPITHELIAL interactions, under the influence of androgens, have been demonstrated to play a key role in human prostate development and prostate cancer (1, 2). Androgens are known to directly stimulate the growth of human prostate cancer cells (3, 4). One of the best studied androgen-sensitive human prostate cancer cell lines is LNCaP, originally isolated from the lymph node of a patient with hormone-refractory, metastatic disease (5). The LNCaP cell line is dependent upon coinoculation with stroma for growth in vivo (2, 6). We recently developed tumors in nude mice by the sc coinoculation of LNCaP cells with human prostate fetal fibroblasts. In that system, we found evidence that the stromal cells were producing and secreting vascular endothelial growth factor (VEGF), a potent angiogenic and vascular permeability factor (VPF) known to enhance tumor growth (7). The present studies were undertaken to determine whether androgens, in addition to their known direct effects on prostate cancer cell growth, enhance prostate cancer growth indirectly via up-regulation of stromal VEGF production.

Folkman (8) and colleagues were the first to demonstrate that angiogenesis, the development of new blood vessels, is an essential step in tumor growth. The process of angiogenesis is tightly regulated by a variety of angiogenic and antiangiogenic factors. Several growth factors have been demonstrated to induce angiogenesis, including basic fibroblast growth factor and platelet-derived growth factor; however, these factors are mitogenic to a variety of cell types (9, 10). VEGF is unique among angiogenic molecules, in that it specifically targets endothelial cells and promotes their proliferation and migration, two essential steps in angiogenesis (11).

VEGF itself has been reported to be produced by many normal and neoplastic cells, and it induces both increased vascular permeability and angiogenesis (12). Treatment of tumors with VEGF-neutralizing antibodies effectively inhibits tumor growth in vivo (7, 13). Enhancing local VEGF concentrations, either by transfection of the VEGF gene or by the addition of exogenous VEGF, increases the tumor take rates, growth rates, and vascular density of prostate and breast cancer cells in nude mice (14, 15). VEGF expression has previously been demonstrated to be up-regulated by hypoxia, cytokines, growth factors, estrogen, and progesterone and down-regulated by glucocorticoids (16, 17, 18, 19, 20, 21, 22). One report demonstrated that castration inhibited tumor VEGF in two androgen-responsive human prostatic cancer xenograft models (23). The present report is the first to demonstrate androgenic up-regulation of VEGF expression in noncancerous stromal cells. These data suggest that androgen-ablative therapies may partially target stroma, resulting in decreased VEGF, decreased vascular permeability, and decreased edema of primary prostate cancers and metastatic lesions.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Tissues
Tissue was obtained from male fetuses (18–24 weeks gestation) at the time of pregnancy interruption and with the approval of the Mount Sinai Medical Center Institutional Review Board. Adult prostatic tissue was obtained from transurethral and retropubic prostatectomies [performed for benign prostatic hyperplasia (BPH)] and radical prostatectomy specimens performed for prostate cancer, again under the guidelines of the Institutional Review Board. All samples were fixed in formalin.

Immunohistochemistry for VEGF expression
For routine histology, specimens were fixed in 10% neutral buffered formalin and embedded in paraffin, and fixed sections were cut and stained with hematoxylin and eosin. For VEGF immunohistochemistry, all steps were carried out in a humidified chamber at room temperature (except incubation with primary antibody) using reagents from Vector Laboratories, Inc. (Burlingame, CA). Sections were deparaffinized, then treated with 3% hydrogen peroxide in PBS for 20 min, followed by three washes in distilled water for 5 min each. Slides were then treated with 5 µg/ml pepsin in 0.01 N HCl (pH 2.5) for 30 min (to block endogenous peroxidases), followed by incubation with with 5 µg/ml saponin in distilled water for 30 min and three washes in PBS for 5 min each. Slides were then blocked for 20 min in normal goat serum. Incubation with polyclonal antibodies to VEGF (0.5 µg/ml) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) was performed overnight at 4 C. Afetr the overnight incubation, slides were washed in PBS twice for 5 min each, then incubated with biotinylated goat antirabbit antibody (dilution 1:200) for 30 min. After two more washes in PBS, an avidin-biotin complex was applied for 30 min, followed by washing in 0.5% Triton X-100 for 30 sec; and application of the chromagen 3,3'-diaminobenzidine was performed for 10 min in the dark. Slides were then counterstained with Harris hematoxylin.

Cell lines and cell culture
With the approval of our Institutional Review Board, fetal fibroblasts were isolated from prostate tissue derived from 18- to 24-week-old gestation fetuses at the time of pregnancy interruption, as previously described (24). Surgical specimens were minced into small cubes and incubated for 48 h in DMEM/Ham’s F12 media (Gibco, Grand Island, NY) with 10% FBS and collagenase type I (1.25 mg/ml; Worthington Biochemical Corp., Freehold, NJ). After collagenase digestion, cells were washed and plated in DMEM/Ham’s F12 with 10% FBS. Only fibroblasts are still visible after the second passage (confirmed by positive immunohistochemical staining for vimentin and negative staining for smooth muscle markers). Thereafter, fibroblast cells were routinely maintained in RPMI 1640 medium with 10% FBS (Gibco). Fibroblast cells from passages 3–5 were used in these studies. For Northern blot, nuclear run-on and actinomycin D (Act D) experiments, subconfluent fibroblast cultures were washed and the medium changed to serum-free, phenol red-free medium containing 0.1% BSA for 24 h. Incubation was continued with and without dihydrotestosterone (DHT) (Sigma Chemical Co., St. Louis, MO) at the doses and time periods indicated.

Isolation of total RNA and Northern blotting
Total RNA extraction from cultured cells and the Northen blot analysis procedures were carried out as described elsewhere (25). Briefly, cells cultured under the desired conditions were harvested, and total RNA was isolated and fractionated on a 1.2% agarose-formaldehyde gel. After transfer to a nitrocellulose membrane, hybridization was performed with an {alpha}-32P-labeled VEGF complementary DNA (cDNA) probe (a generous gift from Dr. K. Claffey, Beth Israel Deaconess Medical Center, Boston, MA). The membranes were subsequently hybridized with a glyceraldehyde-phosphate dehydrogenase (GAPDH) cDNA probe (ATCC, Rockville, MD) to monitor RNA loading. The amounts of VEGF messenger RNA (mRNA) were quantified by laser densitometry (Molecular Dynamics, Inc., Sunnyvale, CA).

Nuclei isolation and nuclear run-on
Nuclei were prepared from prostate fetal fibroblasts by the method of Greenberg and Ziff (26). Briefly, cells were lysed in ice-cold nuclear extraction buffer [10 mM Tris-HCl (pH 7.4), 10 mM NaCl, 3 mM MgCl2, and 0.5% Nonidet P-40) and incubated on ice for 10 min. The nuclei were pelleted at 500 x g at 4 C for 5 min, washed once in nuclear extraction buffer, and repelleted. Washed nuclei were resuspended at 2 x 107 nuclei/200 µl in 40% glycerol, 5 mM MgCl2, 0.1 mM EDTA, and 50 mM Tris-HCl at pH 8.3, and frozen in liquid nitrogen and stored at -70 C.

The transcription assay was a modification of the Howard and Ortlepp method (27). An equal volume of transcription buffer (10 mM Tris-HCl at pH 8.0, 5 mM MgCl2, 300 mM KCl, 0.5 mM dithiothreitol) containing 2 mM GTP, cytidine 5'-triphosphate, ATP, and 200 µCi ({alpha}-32P) uridine 5'-triphosphate was added to each reaction and incubated at 32 C for 40 min. Nuclear RNA was then isolated by the Chomczynski method (28). The RNA pellet was dissolved in sterile 10 mM Tris-HCl (pH 7.2), 1 mM EDTA, and 0.1% SDS and was used as a probe for hybridization. Radiolabeled RNA was hybridized at 42 C for 40 h to nylon membranes containing 8 µg purified human VEGF cDNA (a gift from Dr. K. Claffey). A plasmid containing the Escherichia coli fragments of GAPDH gene served as a control for noninducible genes. The filters were washed in 2x saline-sodium citrate, 0.1% SDS at 22 C, again at 42 C, and finally in 0.1x saline-sodium citrate, 0.1% SDS at 42 C before autoradiography. The bands identified by autoradiography were analyzed by laser densitometry, and values are reported as the relative increases in transcription rate of VEGF after normalizing to the GAPDH transcriptional rate.

Measurement of VEGF RNA stability
Prostate fetal fibroblasts were routinely maintained in RPMI 1640 with 10% FBS. For treatment with DHT, subconfluent cells were washed and changed to serum-free, phenol red-free medium containing 0.1% BSA for 24 h. Incubation was continued with and without DHT (10 nM) for 2 h. At time zero, Act D (100 µg/ml) was added, and cells were harvested at varying time points. Total RNA was prepared and the level of VEGF transcripts determined by Northern blot analysis.

Preparation of prostate fetal fibroblast-conditioned medium
Prostate fetal fibroblasts were plated at 1 x 105 cells/well in six-well cluster dishes with 2 ml RPMI 1640 medium containing 10% FBS. After 3 days, cells were washed and changed to serum-free, phenol red-free medium containing 0.1% BSA. Incubation was continued with and without DHT (10 nM) for the time periods indicated. The medium was then removed, centrifuged at 1000 g for 10 min to remove suspended cells, and stored at -20 C for enzyme-linked immunosorbent assay (ELISA) and endothelial cell migration assays.

ELISA for VEGF
Conditioned media, prepared from prostate fetal fibroblasts at the indicated time points after the addition of DHT (10 nM), were assayed for VEGF protein using a sandwich ELISA, according to the manufacturer’s instructions (Intergen Co., Purchase, NY). Results of conditioned medium were expressed as amount of VEGF/106 cells/24 h.

Statistical analysis
Data are expressed as mean ± SEM. For time course and dose-response experiments, results were statistically analyzed using ANOVA.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
VEGF expression in human prostate specimens by immunohistochemistry
Figure 1Go demonstrates the results of immunohistochemical staining for VEGF expression in human prostate specimens. In the fetal prostate, strong VEGF expression was noted in the smooth muscle cells (Fig. 1AGo). The higher power view of the fetal prostate (Fig. 1BGo) demonstrates that both the immature mesenchyme (M) and the fetal epithelial (E) cells also demonstrate some VEGF expression. In BPH, there is strong VEGF expression that is limited to the stromal cells, with no appreciable expression in the epithelium (Fig. 1CGo). In contrast, in prostate cancer, VEGF expression is demonstrable in both the stroma and the cancerous E cells (Fig. 1DGo). These data demonstrate that VEGF is expressed in the stromal cells of the fetal, adult hyperplastic and cancerous human prostate, whereas E cell VEGF expression is most pronounced in the cancerous prostate.



View larger version (127K):
[in this window]
[in a new window]
  		Figure 1. Immunohistochemical localization of VEGF expression in the human prostate. A and B, Low- and high-power magnifications, respectively, demonstrating VEGF expression in the stromal cells of the human fetal prostate; A, strong VEGF expression is noted in the smooth muscle cells of the human fetal prostate (SM), with less expression in the E cells (magnification, 40x); B, the higher power magnification demonstrates that, in addition to the dense VEGF staining in the smooth muscle cells, there is some VEGF staining in the fetal prostate E cells and the surrounding immature mesenchyme (magnification, 200x); C, in adult BPH, there is strong VEGF expression in the stroma (S), with no expression in the epithelium (E) (magnification, 100x); D, In prostate cancer, both the cancerous E cells and the surrounding stroma (S) stain for VEGF expression (magnification, 200x).

 
Effect of androgen on VEGF mRNA levels
To determine whether androgen modulates the production of VEGF by human fetal prostatic fibroblasts, primary cultures were incubated in serum-free medium with DHT for various times. Fetal prostatic fibroblasts demonstrate a low basal level of VEGF mRNA expression. Two VEGF transcripts (4.2 and 3.7 kb) are discernible, which represent hybridization of the cDNA probe to the known splice variants of VEGF mRNA (29). VEGF mRNA levels were increased as early as 1 h, with a maximum response (approximately twice that demonstrated at time 0) demonstrable 2 h after the addition of 10 nM DHT. VEGF mRNA levels began to decline at 3 h and were almost back to baseline 8 h after DHT addition (Fig. 2Go).



View larger version (33K):
[in this window]
[in a new window]
  		Figure 2. Induction of VEGF mRNA by DHT. Primary cultures of human fetal prostatic fibroblasts (passage 3) were grown in serum-free medium for 24 h. Incubations were continued with or without 10 nM DHT for various times at 37 C. Upper panel, Expression of VEGF mRNA was assayed by Northern blot analysis. Membranes were also hybridized with a GAPDH probe to assess loading differences. Twenty-five micrograms of total RNA were loaded in each lane. Lower panel, The data in the upper panel were quantified using a densitometer and are presented as a ratio of VEGF mRNA to GPDPH mRNA. Values shown are the mean ± SEM (n = 3). *, P < 0.05; **, P < 0.01 vs. control.

 
The dose dependence of the DHT effect on VEGF mRNA levels was next characterized. As shown in Fig. 3Go, a modest enhancement in VEGF mRNA was discernible after treatment with 1 nM DHT for 2 h. Higher concentrations of DHT further increased VEGF mRNA expression, with saturation of this effect noted in the presence of 10 nM DHT, indicating a dose-dependent induction of VEGF transcripts by DHT.



View larger version (32K):
[in this window]
[in a new window]
  		Figure 3. Dose dependence of VEGF induction. Primary cultures of human fetal prostatic fibroblasts at passage 3 were grown in serum-free medium for 24 h. Incubations were continued with or without various concentrations of DHT for an additional 2 h at 37 C. Upper panel, Expression of VEGF mRNA was assayed by Northern blot analysis. Membranes were also hybridized with a GAPDH probe to assess loading differences. Twenty-five micrograms of total RNA were loaded in each lane. Lower panel, The data in the upper panel were quantified using a densitometer and are presented as a ratio of VEGF mRNA to GAPDH mRNA. Values shown are the mean ± SEM (n = 3). *, P < 0.05; **, P < 0.01 vs. control.

 
Effect of androgen on VEGF protein production
To examine whether the augmented expression of VEGF mRNA was accompanied by an increase in VEGF protein production, an ELISA was performed on fibroblast-conditioned medium. In the presence of 10 nM DHT, VEGF protein secretion was maximal 4 h after DHT addition, began to decline by 8 h, and returned to baseline levels 16 h after androgen addition (Fig. 4Go).



View larger version (16K):
[in this window]
[in a new window]
  		Figure 4. Up-regulation of VEGF protein secretion by DHT. Primary cultures of human fetal prostatic fibroblasts at passage 3 were grown in serum-free medium for 24 h. Incubations were continued with or without 10 nM DHT for various times at 37 C. The secretion of VEGF protein to the culture medium in triplicate cellular incubates was quantified using ELISA and was normalized by cell number. The data represent the mean values ± SEM. *, P < 0.05; **, P < 0.01 vs. control.

 
The concentration dependence of VEGF protein induction was also examined by ELISA. As shown in Fig. 5Go, VEGF protein secretion increased progressively with the increased concentration of DHT, starting at 1 nM, with a peak stimulation at 10 nM. Higher doses of DHT had no further effect on VEGF protein production.



View larger version (18K):
[in this window]
[in a new window]
  		Figure 5. Dose dependence of DHT effect on VEGF protein secretion. Primary cultures of human fetal prostatic fibroblasts at passage 3 were grown in serum-free medium for 24 h. Incubations were continued with or without various concentrations of DHT for an additional 4 h at 37 C. The secretion of VEGF protein to the culture medium in triplicate cellular incubates was quantified using ELISA and was normalized by cell number. The data represent the mean values ± SEM. *, P < 0.05; **, P < 0.01 vs. control.

 
Mechanisms of VEGF induction by androgen
The mechanisms by which DHT increases expression of VEGF mRNA were then defined. Nuclear run-on assays were used to determine whether the accumulation of VEGF transcripts is caused by an increased rate of transcription for VEGF mRNA. As shown in Fig. 6Go, untreated fetal prostatic fibroblasts exhibited detectable levels of VEGF transcription. The addition of 10 nM DHT resulted in an increase in this process by about 40% within 1 h, with a maximal response (doubling over nontreated control) evident 2 h after DHT addition. Thereafter, the rate of transcription diminished, although it remained above control level at 4 h after DHT addition. DHT treatment did not alter the transcription rate of the control GAPDH gene.



View larger version (27K):
[in this window]
[in a new window]
  		Figure 6. Transcriptional regulation of VEGF production. Primary cultures of human fetal prostatic fibroblasts were cultured with 10 nM DHT for various times at 37 C. Transcription was then determined by nuclear run-on assay, as described under Materials and Methods. The data were quantified using a densitometer, and the densities are normalized to GAPDH levels. The results are reported as the percentage increase in VEGF mRNA, relative to the control level in untreated cells.

 
To determine whether the increases in steady-state VEGF mRNA levels were caused by an alteration in transcript stability, we examined the rate of decay of the VEGF mRNA, using Act D to inhibit transcription from DHT-treated and control cells. Fetal prostatic fibroblasts were stimulated with 10 nM DHT for 2 h. Act D was added, and the cells were harvested at various times for Northern blot analysis of VEGF mRNA. As shown in Fig. 7Go, DHT did not significantly effect the rate of decay of the VEGF mRNA in these fibroblast cells. The estimated half-life of VEGF mRNA was 98 ± 11.6 min vs. 93 ± 8.1 min in the DHT(-) and DHT(+) cultures, respectively. These results imply that the accumulation of VEGF mRNA in response to DHT was caused by transcriptional activation of the VEGF gene, with no significant effect on VEGF mRNA stability.



View larger version (15K):
[in this window]
[in a new window]
  		Figure 7. Stability of VEGF mRNA. Primary cultures of human fetal prostatic fibroblasts were exposed to 10 nM DHT (•–•) or vehicle ({triangledown}–{triangledown}) for 2 h at 37 C before the addition of Act D (0.1 mg/ml). Total RNA was extracted from the cells at the indicated times after Act D administration, fractionated by electrophoresis, and transferred to nitrocellulose membranes. The Northern blots were hybridized to a cDNA probe for VEGF. To correct for differences in loading, membranes were also hybridized with a GAPDH cDNA probe. Results were quantified using a densitometer and is presented as a ratio of VEGF mRNA to GAPDH mRNA. The corrected density is plotted as a percentage of time zero value against time. Each point represents mean values ± SEM (n = 3).

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
The development of new blood vessels, either through vasculogenesis or angiogenesis, is an essential step in physiologic and pathophysiologic processes. Although there are many known angiogenic factors, recent attention has focused on VEGF because of increasing reports demonstrating its essential role in fetal development and tumor angiogenesis. Knockout of a single VEGF allele (30, 31) or either of the two high-affinity binding VEGF-receptors (32, 33) results in embryonic lethality in transgenic mice. Inhibition of VEGF activity with neutralizing antibodies suppresses the growth of tumors in nude mice (7, 13, 34).

The importance of VEGF in the prostate is beginning to be elucidated. Recent studies have demonstrated VEGF expression in human BPH and prostate cancer specimens (35, 36). In one of those reports (35), there is immunocytochemical evidence of VEGF expression in BPH E cells and noncancerous stroma. This confirms a previous study in which substantial quantities of VEGF were demonstrated in the semen of healthy males (37). In this report, we demonstrate strong VEGF expression in the stroma of the human fetal, adult hyperplastic and cancerous prostate. In contrast, noncancerous fetal and adult prostate E cells express little VEGF, with stronger expression noted in prostate cancer specimens. All human prostate cancer cell lines tested to date express some VEGF (23). There is evidence that VEGF secretion from the androgen-sensitive human prostate cancer cell line LNCaP is increased by androgens (our unpublished results and Ref. 38). Although LNCaP cells do express small amounts of VEGF, we have demonstrated that the dependence of this cell line on stromal coinoculation for growth sc in nude mice may be partially explained by the expression of VEGF in the stromal cells (7).

In this report, we demonstrate androgenic regulation of VEGF expression in human prostate fetal fibroblasts. The androgenic effect on VEGF mRNA levels was rapid, with increased transcription noted as early as 1 h after androgen addition, and peak increases noted 2 h after androgen addition. This is consistent with previous reports demonstrating a rapid induction of VEGF mRNA after treatment with either estrogen or insulin-like growth factor 1 (IGF-1) (19, 39, 40). Our findings differ from those reported with IGF-1, in that androgens primarily increased VEGF mRNA transcription with no effect on VEGF mRNA stability, whereas IGF-1 did increase the VEGF mRNA stability (18). The rapid induction of VEGF mRNA transcription is consistent with a direct effect of androgens on the VEGF promoter. However, to date, a functional androgen response element has not been identified in the VEGF gene. It is possible that androgens have both direct and indirect effects, the latter of which may be mediated by androgenic effects on other growth factors, such as IGF-1.

The increase in VEGF mRNA is maximal at 2 h and was followed shortly thereafter by an increase in VEGF-secreted protein (increased VEGF-secreted protein maximally after 4 h). Androgens induce a doubling of VEGF mRNA transcription rates, with a resultant doubling of VEGF protein levels. The demonstrated increase in VEGF-secreted protein is probably a result of increased synthesis. However, we cannot rule out the possibility that androgens also have an effect on VEGF protein secretion.

The prostate was the first organ system in which the importance of stroma in mediating the effects of androgen on epithelium was demonstrated (1, 2). Prostatic stroma produces the type 2 isozyme of steroid 5{alpha}-reductase, which converts testosterone to its more potent metabolite, DHT, intracellularly (41). Prostatic stromal cells also produce and secrete keratinocyte growth factor (KGF) under androgenic regulation, which promotes branching morphogenesis in the mouse seminal vesicle and ductal branching of the rat ventral prostate (42, 43). We recently demonstrated that KGF functions as a stromal andromedin that increases prostate-specific antigen secretion in human fetal prostate organ cultures (44). The present report demonstrates that these same stromal cells, which mediate the effects of androgens on neighboring E cells, also serve as mediators of androgenic effects on local endothelial cells.

Androgens have known direct effects on normal and cancerous prostate E cells. Recent studies have demonstrated that testosterone also targets endothelial cells, increasing the weight of blood vessel walls, blood vessel lumina, and endothelial cells, as well as increasing endothelial cell proliferation rates in the rat ventral prostate (45). The effect of testosterone on the vasculature in that report was more immediate than its effects on E cells. Androgen ablation results in a rapid decrease in blood vessel density in rat prostate cancers (46). We propose that these rapid effects are caused by androgenic effects on VEGF protein levels. VEGF was originally described as VPF and is reported to be 50,000 times more potent than histamine in its ability to enhance vascular permeability (47). Rapid changes in VEGF/VPF secretion would most likely be first manifested clinically as changes in vascular permeability and edema.


   Footnotes
 
1 This work was supported by grants-in-aid from the T. J. Martell Foundation for Leukemia, Cancer, and Aids Research; and the Hans E. Schapira, M.D., Foundation for Urologic Research. Back

Received February 25, 1998.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Cunha GR, Chung LWK, Shannon JM, Aguchi O, Fuji H 1983 Hormone-induced morphogenesis and growth: role of mesenchymal-epithelial interactions. Recent Prog Horm Res 39:559–598
  2. Chung LWK, Gleave ME, Hsieh JT, Hong S-J, Zhau HYE 1991 Reciprocal mesenchymal-epithelial interaction affecting prostate tumor growth and hormonal responsiveness. Cancer Surv 11:91–121[Medline]
  3. Kyprianou N, English HF, Isaacs JT 1990 Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 50:3748–3753[Abstract/Free Full Text]
  4. Kirschenbaum A, Ren M, Levine AC 1993 Enhanced androgen sensitivity in serum-free medium of a subline of the LNCaP human prostate cancer cell line. Steroids 58:439–443[CrossRef][Medline]
  5. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Ming Chu T, Mirand EA, Murphy GP 1983 LNCaP model of human prostatic carcinoma. Cancer Res 43:1809–1813[Abstract/Free Full Text]
  6. Gleave ME, Hsieh JT, Von Eschenbach AC, Chung LWK 1992 Prostate and bone fibroblasts induce human prostate cancer growth in vivo: implications for bidirectional tumor-stromal cell interaction in prostate carcinoma growth and metastasis. J Urol 147:1151–1159[Medline]
  7. Kirschenbaum A, Wang J-P, Ren M, Schiff JD, Aaronson SA, Droller MJ, Ferrara N, Holland JF, Levine AC 1997 Inhibition of vascular endothelial cell growth factor suppresses the in vivo growth of human prostate tumors. Urol Oncol 3:3–10
  8. Folkman J 1990 What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4–7[Free Full Text]
  9. Hanahan D, Folkman J 1996 Patterns and emerging mechanisms of angiogenic switch during tumorigenesis. Cell 86:353–364[CrossRef][Medline]
  10. Folkman J 1995 Tumor angiogenesis. In: Mendelssohn J, Howley P, Liotta LA, Israel M (eds) The Molecular Basis of Cancer. WS Saunders, Philadelphia, pp 206–232
  11. Klagsbrun M, D’Amore PA 1991 Regulation of angiogenesis. Annu Rev Physiol 53:217–239[CrossRef][Medline]
  12. Ferrara N, Houck K, Jakeman L, Leung DW 1992 Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 13:18–32[Abstract/Free Full Text]
  13. Kim KJ, Li B, Winer J, Armamini M, Gillett N, Phillips HS, Ferrara N 1993 Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362:841–844[CrossRef][Medline]
  14. Zhang H-T, Craft P, Scott PAE, Ziche M, Weich HA, Harris AL, Bicknell R 1995 Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. J Natl Cancer Inst 87:213–219[Abstract/Free Full Text]
  15. Gridley DA, Andres ML, Slater JM 1997 Enhancement of prostate cancer xenograft growth with whole-body radiation and vascular endothelial growth factor. Anticancer Res 17:923–928[Medline]
  16. Hlatky L, Tsionou C, Hahnfeldt P, Coleman CN 1994 Mammary fibroblasts may influence breast tumor angiogenesis via hypoxia-induced vascular endothelial growth factor up-regulation and protein expression. Cancer Res 54:6083–6086[Abstract/Free Full Text]
  17. Cohen T, Nahari D, Cerem LW, Neufeld G, Levi B-Z 1996 Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 271:736–741[Abstract/Free Full Text]
  18. Warren RS, Yuan H, Matli MR, Ferrara N, Donner DB 1996 Induction of vascular endothelial growth factor by insulin-like growth factor I in colorectal carcinoma. J Biol Chem 271:29483–29488[Abstract/Free Full Text]
  19. Hyder SM, Stancel GM, Chiappetta C, Murthy L, Boettger-Tong HL, Makela S 1996 Uterine expression of vascular endothelial growth factor is increased by estradiol and tamoxifen. Cancer Res 56:3954–3960[Abstract/Free Full Text]
  20. McLaren J, Prentice A, Charnock-Jones DS, Millican SA, Muller KH, Sharkey AM, Smith SK 1996 Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids. J Clin Invest 98:482–489[Medline]
  21. Nakamura J, Savinov A, Lu Q, Brodie A 1996 Estrogen regulates vascular endothelial growth/permeability factor expression in 7,12 dimethylbenz(a)anthracene-induced rat mammary tumors. Endocrinology 137:5589–5596[Abstract]
  22. Heiss JD, Papavassiliou E, Merrill MJ, Nieman L, Knightly JJ, Walbridge S, Edwards NA, Oldfield EH 1996 Mechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats. J Clin Invest 98:1400–1408[Medline]
  23. Joseph IBJK, Isaacs JT 1997 Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers. Cancer Res 57:1054–1057[Abstract/Free Full Text]
  24. Levine AC, Ren M, Huber GK, Kirschenbaum A 1992 The effect of androgen, estrogen, and growth factors on the proliferation of cultured fibroblasts derived from human fetal and adult prostates. Endocrinology 130:2413–2419[Abstract/Free Full Text]
  25. Liu XH, Wiley HS, Meikle AW 1993 Androgens regulate proliferation of human prostate cancer cells in culture by increasing transforming growth factor-2 and epidermal growth factor receptor. J Clin Endocrinol Metab 77:1472–1478[Abstract]
  26. Greenberg ME 1988 Identification of newly transcribed RNA. In: Ausubel FM, Brent R, Kingston RE, Moore DD, Smith JA, Seidman JG, Strahl K (eds) Current Protocols in Molecular Biology. John Wiley and Sons, New York, pp 4.10.1–4.10.8
  27. Howard LA, Ortlepp SA 1989 A simplification of the nuclear run-off transcription assay. Biotechniques 7:940–942[Medline]
  28. Chomczynski P, Sacchi N 1987 Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156–159[Medline]
  29. Claffey KP, Brown LF, del Aguila LF, Tognazzi K, Yeo K-T, Manseau EF, Dvorak HF 1996 Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res 56:172–181[Abstract/Free Full Text]
  30. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gersenstein M, Fahrig M, Vandenhhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W, Nagy A 1996 Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380:435–439[CrossRef][Medline]
  31. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O’Shea KD, Powell-Braxton L, Hillan KJ, Moore MW 1996 Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380:439–442[CrossRef][Medline]
  32. Shalaby F, Rossant J, Yamaguchi TP, Gersenstein M, Wu XF, Breitman ML, Schuh AC 1995 Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376:62–66[CrossRef][Medline]
  33. Fong GH, Rossant J, Gersenstein M, Breitman ML 1995 Role of the Flt-1 tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376:66–70[CrossRef][Medline]
  34. Asano M, Yukita A, Matsumoto T, Kondo S, Suzuki H 1995 Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor. Cancer Res 55:5296–5301[Abstract/Free Full Text]
  35. Jackson MW, Bentel JM, Tilley WD 1997 Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J Urol 157:2323–2328[CrossRef][Medline]
  36. Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP, Kreutzer DL 1997 Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. J Urol 157:2329–2333[CrossRef][Medline]
  37. Brown LF, Yeo K-T, Berse B, Morgentaler A, Dvorak HF, Rosen S 1995 Vascular permeability factor (vascular endothelial growth factor) is strongly expressed in the normal male genital tract and is present in substantial quantities in semen. J Urol 154:576–579[CrossRef][Medline]
  38. Folkman J 1998 Editorial: is tissue mass regulated by vascular endothelial cells: prostate as the first evidence. Endocrinology 139:441–442[Free Full Text]
  39. Cullanin-Bove K, Koos RD 1993 Vascular endothelial growth factor/vascular permeability factor expression in the rat uterus: rapid stimulation by estrogen correlates with estrogen-induced increases in uterine capillary permeability and growth. Endocrinology 133:829–837[Abstract/Free Full Text]
  40. Punglia RS, Lu M, Hsu J, Kuroki M, Tolentino MJ, Keough K, Levy AP, Levy NS, Goldberg MA, D’Amato RJ, Adamis AP 1997 Regulation of vascular endothelial growth factor expression by insulin-like growth factor I. Diabetes 46:1619–1626[Abstract]
  41. Levine AC, Wang J-P, Ren M, Eliashvili E, Russell DW, Kirschenbaum A 1996 Immunohistochemical localization of steroid 5{alpha}-reductase 2 in the human male fetal reproductive tract and adult prostate. J Clin Endocrinol Metab 81:384–389[Abstract]
  42. Alarid ET, Rubin JS, Young P, Chedid M, Ron D, Aaronson SA, Cunha GR 1994 Keratinocyte growth factor functions in epithelial induction during seminal vesicle development. Proc Natl Acad Sci USA 91:1074–1078[Abstract/Free Full Text]
  43. Sugimura Y, Foster BW, Hom YK, Lipschutz JH, Rubin JS, Finch PW, Aaronson SA, Hayashi N, Kawamura J, Cunha GR1996 Keratinocyte growth factor (KGF) can replace testosterone in the ductal branching morphogenesis of the rat ventral prostate. Int J Dev Biol 40:941–951
  44. Levine AC, Liu X-L, Ren M, Wang J-P, Schiff JD, Diamond EJ, Finch PW, Aaronson SA, Kirschenbaum A 1998 Androgenic effects on prostate specific antigen secretion by human fetal prostate are mediated by keratinocyte growth factor. Mol Urol 2:71–78
  45. Franck-Lissbrant I, Haggstrom S, Damber J-E, Bergh A 1998 Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats. Endocrinology 139:451–456[Abstract/Free Full Text]
  46. Hartley-Asp B, Vukanovic J, Joseph IBJK, Strandgarden K, Polacek J, Isaacs JT 1997 Anti-angiogenic treatment with Linomide as adjuvant to surgical castration in experimental prostate cancer. J Urol 158:902–907[CrossRef][Medline]
  47. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Garvery VS, Dvorak HF 1983 Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219:983–985[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Endocr Relat CancerHome page
M.-L. Zhu and N. Kyprianou
Androgen receptor and growth factor signaling cross-talk in prostate cancer cells
Endocr. Relat. Cancer, December 1, 2008; 15(4): 841 - 849.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
G.-S. Hwang, S.-W. Wang, W.-M. Tseng, C.-H. Yu, and P. S. Wang
Effect of hypoxia on the release of vascular endothelial growth factor and testosterone in mouse TM3 Leydig cells
Am J Physiol Endocrinol Metab, June 1, 2007; 292(6): E1763 - E1769.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
K. Horii, Y. Suzuki, Y. Kondo, M. Akimoto, T. Nishimura, Y. Yamabe, M. Sakaue, T. Sano, T. Kitagawa, S. Himeno, et al.
Androgen-Dependent Gene Expression of Prostate-Specific Antigen Is Enhanced Synergistically by Hypoxia in Human Prostate Cancer Cells
Mol. Cancer Res., April 1, 2007; 5(4): 383 - 391.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
A. Kirschenbaum, X.-H. Liu, S. Yao, G. Narla, S. L. Friedman, J. A. Martignetti, and A. C. Levine
Sex steroids have differential effects on growth and gene expression in primary human prostatic epithelial cell cultures derived from the peripheral versus transition zones
Carcinogenesis, February 1, 2006; 27(2): 216 - 224.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. R. Gray, W. J. Huss, J. M. Yau, L. E. Durham, E. S. Werdin, W. K. Funkhouser Jr., and G. J. Smith
Short-Term Human Prostate Primary Xenografts: An in Vivo Model of Human Prostate Cancer Vasculature and Angiogenesis
Cancer Res., March 1, 2004; 64(5): 1712 - 1721.
[Abstract] [Full Text] [PDF]

Home page
 J AndrolHome page
H. Schwarzenbach, G. Chakrabarti, H. J. Paust, and A. K. Mukhopadhyay
Gonadotropin-Mediated Regulation of the Murine VEGF Expression in MA-10 Leydig Cells
J Androl, January 1, 2004; 25(1): 128 - 139.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. J. Mabjeesh, M. T. Willard, C. E. Frederickson, H. Zhong, and J. W. Simons
Androgens Stimulate Hypoxia-inducible Factor 1 Activation via Autocrine Loop of Tyrosine Kinase Receptor/Phosphatidylinositol 3'-Kinase/Protein Kinase B in Prostate Cancer Cells
Clin. Cancer Res., July 1, 2003; 9(7): 2416 - 2425.
[Abstract] [Full Text] [PDF]

Home page
 Biol. Reprod.Home page
R. J. K. Anand, H.-J. Paust, K. Altenpohl, and A. K. Mukhopadhyay
Regulation of Vascular Endothelial Growth Factor Production by Leydig Cells In Vitro: The Role of Protein Kinase A and Mitogen-Activated Protein Kinase Cascade
Biol Reprod, May 1, 2003; 68(5): 1663 - 1673.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. A. Tuxhorn, S. J. McAlhany, T. D. Dang, G. E. Ayala, and D. R. Rowley
Stromal Cells Promote Angiogenesis and Growth of Human Prostate Tumors in a Differential Reactive Stroma (DRS) Xenograft Model
Cancer Res., June 1, 2002; 62(11): 3298 - 3307.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. W. Jackson, J. S. Roberts, S. E. Heckford, C. Ricciardelli, J. Stahl, D. J. Horsfall, and W. D. Tilley
A Potential Autocrine Role for Vascular Endothelial Growth Factor in Prostate Cancer
Cancer Res., February 1, 2002; 62(3): 854 - 859.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. E. Taplin and S.-M. Ho
The Endocrinology of Prostate Cancer
J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3467 - 3477.
[Full Text] [PDF]

Home page
 CMAJHome page
J. I. Izawa and C. P.N. Dinney
The role of angiogenesis in prostate and other urologic cancers: a review
Can. Med. Assoc. J., March 1, 2001; 164(5): 662 - 670.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W. J. Huss, C. F. Hanrahan, R. J. Barrios, J. W. Simons, and N. M. Greenberg
Angiogenesis and Prostate Cancer: Identification of A Molecular Progression Switch
Cancer Res., March 1, 2001; 61(6): 2736 - 2743.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
J. H. Pinthus, T. Waks, D. G. Schindler, A. Harmelin, J. W. Said, A. Belldegrun, J. Ramon, and Z. Eshhar
WISH-PC2: A Unique Xenograft Model of Human Prostatic Small Cell Carcinoma
Cancer Res., December 1, 2000; 60(23): 6563 - 6567.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
M. I. Koukourakis, A. Giatromanolaki, P. E. Thorpe, R. A. Brekken, E. Sivridis, S. Kakolyris, V. Georgoulias, K. C. Gatter, and A. L. Harris
Vascular Endothelial Growth Factor/KDR Activated Microvessel Density versus CD31 Standard Microvessel Density in Non-Small Cell Lung Cancer
Cancer Res., June 1, 2000; 60(11): 3088 - 3095.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. M. Hyder, Z. Nawaz, C. Chiappetta, and G. M. Stancel
Identification of Functional Estrogen Response Elements in the Gene Coding for the Potent Angiogenic Factor Vascular Endothelial Growth Factor
Cancer Res., June 1, 2000; 60(12): 3183 - 3190.
[Abstract] [Full Text]

Home page
 EndocrinologyHome page
R. M. Adam, J. G. Borer, B. J. Williams, J. A. Eastham, K. R. Loughlin, and M. R. Freeman
Amphiregulin Is Coordinately Expressed with Heparin-Binding Epidermal Growth Factor-Like Growth Factor in the Interstitial Smooth Muscle of the Human Prostate
Endocrinology, December 1, 1999; 140(12): 5866 - 5875.
[Abstract] [Full Text]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Levine, A. C.
Right arrow Articles by Kirschenbaum, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Levine, A. C.
Right arrow Articles by Kirschenbaum, A.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals